• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Bacterium-like particles for efficient immune stimulation of existing vaccines and new subunit vaccines in mucosal applications

tetano

tetano

Editor, Senior Moderator
Front Immunol. 2013 Sep 17;4:282. doi: 10.3389/fimmu.2013.00282.
Bacterium-like particles for efficient immune stimulation of existing vaccines and new subunit vaccines in mucosal applications.
Van Braeckel-Budimir N, Haijema BJ, Leenhouts K.
Source

Mucosis BV , Groningen , Netherlands.
Abstract

The successful development of a mucosal vaccine depends critically on the use of a safe and effective immunostimulant and/or carrier system. This review describes the effectiveness and mode of action of an immunostimulating particle, derived from bacteria, used in mucosal subunit vaccines. The non-living particles, designated bacterium-like particles are based on the food-grade bacterium Lactococcus lactis. The focus of the overview is on the development of intranasal BLP-based vaccines to prevent diseases caused by influenza and respiratory syncytial virus, and includes a selection of Phase I clinical data for the intranasal FluGEM vaccine.
KEYWORDS:

Lactococcus lactis, RSV vaccines, carrier-adjuvant, influenza vaccines, mucosal vaccine technology, particles

PMID:
24062748
[PubMed]
PMCID:
PMC3775300

Free full text

http://www.ncbi.nlm.nih.gov/pubmed/24062748
 
You must log in or register to reply here.
Back
Top Bottom